Title |
Adult Leukemia Research Center
|
Institution |
FRED HUTCHINSON CANCER RESEARCH CENTER, SEATTLE, WA
|
Principal Investigator |
APPELBAUM, FREDERICK
|
NCI Program Director |
William Merritt
|
Cancer Activity |
Clinical Oncology
|
Division |
DCTD
|
Funded Amount |
$4,225,448
|
Project Dates |
12/22/1997 - 06/30/2017
|
Fiscal Year |
2012
|
Project Type |
Grant
|
Research Topics w/ Percent Relevance |
Cancer Types w/ Percent Relevance |
Aging (14.0%)
Bone Marrow Transplantation (52.0%)
Cancer (100.0%)
Cancer Survivorship (18.0%)
Chronic Myeloproliferative Disorders (4.0%)
Genetic Testing (12.0%)
Organ Transplantation Research (52.0%)
|
Hodgkins disease (9.0%)
Leukemia (81.0%)
Non Hodgkins Lymphoma (9.0%)
|
Research Type |
Resources and Infrastructure
Systemic Therapies - Clinical Applications
Resources and Infrastructure Related to Treatment and the prevention of recurrence
Patient Care and Survivorship Issues
|
Abstract |
DESCRIPTION (provided by applicant): The overall goal of this program project is to improve allogeneic hematopoietic cell transplantation (HCT) as treatment for hematological malignancies. Specifically we proposed laboratory and clinical studies to broaden the availability of transplantation, to decrease the incidence and severity of graft-versus-host disease, and to reduce the incidence of malignant disease recurrence post transplant. Four individual projects are proposed:
1. Immunogenetics of Graft-versus-host Disease.
2. Nonmyeloablative Hematopoietic Cell Allotransplants.
3. Specific Adoptive Immunotherapy of Myeloid Malignancy.
4. Targeting T Cell Reactivity for Leukemia Eradication.
In addition, core support is requested in biostatistics, molecular diagnostics, cell processing, long-term follow-up, and administration.
Our ability to successfully carry out the proposed work is greatly benefited by: (1) the existence of a large group of investigators all focused on the general topic of HCT; (2) strong preclinical research programs at our Center in support of this topic; and, (3) treatment of >500 transplant patients at our Center each year |